BIOLINERX LTD-SPONS ADR
BLRXNASDAQTrading Snapshot
- Day Range
- $2.73 – $2.79
- 52-Week Range
- $2.15 – $4.56
- Volume
- $1.67B
- Avg Volume
- $1.29B
- Shares Outstanding
- 4.4M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $477,000
- P/E Ratio
- -1.4
- P/S Ratio
- 9.3x
- EPS (TTM)
- $-0.05
- Dividend Yield
- 0.00%
Why Investors Own BLRX
- ✓High-growth profile — revenue up +44.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIOLINERX LTD-SPONS ADR
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.